Two AI-driven advances landed this week: the Baker lab released RFdiffusion3 as open source, demonstrating de novo designs for DNA-binding proteins and catalytic enzymes, and Terray Therapeutics announced its first discovery milestone under a multi-target collaboration with Bristol Myers Squibb. RFdiffusion3 extends atom-level generative protein design, offering proof-of-concept in binder and enzyme design and promising faster, higher‑resolution protein engineering for therapeutics and synthetic biology. Terray’s milestone validates its Experimentation Meets Machine Intelligence (EMMI) platform and high-throughput tArray hardware, which the company says enables measurement of binding at previously unreachable scale. Terray reported its dataset now spans billions of binding measurements and that the BMS-nominated target represents a “novel and difficult-to-drug” challenge—an early commercial endorsement of AI-enabled discovery approaches.